The hepatic drug-metabolizing cytochrome P-450 (CYP) enzymes are down-regulated during inflammation. In vitro studies with hepatocytes have shown that the cytokines released during inflammatory responses are largely responsible for this CYP repression. However, the signaling pathways and the cytokine-activated factors involved remain to be properly identified. Our research has focused on the negative regulation of CYP3A4 (the major drug-metabolizing human CYP) by interleukin 6 (IL-6) (the principal regulator of the hepatic acute-phase response). CYP3A4 down-regulation by IL-6 requires activation of the glycoprotein receptor gp130; however, it does not proceed through the JAK/STAT pathway, as demonstrated by the overexpression of a dominant-negative STAT3 factor by means of an adenoviral vector. The involvement of IL-6-activated kinases such as extracellular signal-regulated kinase ERK1/2 or p38 is also unlikely, as evidenced by the use of specific chemical inhibitors. It is noteworthy that IL-6 caused a moderated induction in the mRNA of the transcription factor C/EBPβ (CCAATenhancer binding protein β) and a marked increase in the translation of C/EBPβ-LIP, a 20-kDa C/EBPβ isoform lacking a transactivation domain. Adenovirus-mediated expression of C/EBPβ-LIP caused a dose-dependent repression of CYP3A4 mRNA, whereas overexpression C/EBPα and C/EBPβ-LAP (35 kDa) caused a significant induction. Our results support the idea that IL-6 down-regulates CYP3A4 through translational induction of C/EBPβ-LIP, which competes with and antagonizes constitutive C/EBP transactivators. From a clinical point of view, these findings could be relevant in the development of therapeutic cytokines with a less repressive effect on hepatic drug-metabolizing enzymes.
in hepatocytes contain homo-and heterodimers of C/EBPα and C/EBPβ (21) but after an APR these complexes become enriched in C/EBPβ and C/EBPδ by different mechanisms (22) (23) (24) (25) (26) (27) (28) ). An additional degree of complexity comes from the fact that the C/EBPβ mRNA directs production of two isoforms (29) : a 35-kDa LAP (liver-enriched transcriptional activating protein) and a 20-kDa LIP (liver-enriched transcriptional inhibitory protein), whose relative concentrations change dramatically during the APR (30) .
The mechanism by which the same inflammatory signal, IL-6, can simultaneously activate APPs and down-regulate other hepatic genes such as CYPs is intriguing. Contrary to extensive knowledge about the regulation of APPs by cytokines, little is known about the mechanism governing CYP down-regulation in hepatocytes. Indeed, no mechanistic studies have been conducted to date to elucidate how IL-6 leads to the repression of constitutive human hepatic CYPs.
In the present study, we attempted to elucidate the mechanisms by which IL-6 down-regulates the expression of the human hepatic CYP3A4 in human hepatocytes and hepatomas, with special attention to the transduction mechanisms and the transcription factors involved. The experimental evidence obtained excluded a significant role of the JAK/STAT and the SHP-2/Ras/MAPK pathways in the down-regulation of CYP3A4. The results of our research point to a translational induction of C/EBPβ-LIP as the determining event. LIP, by competing with other constitutive C/EBP-activating factors, particularly C/EBPα, down-regulates the expression of human CYP3A4. We have shown this mechanism to operate in human hepatocytes.
MATERIALS AND METHODS

Cytokines and reagents
Recombinant human IL-6, with a specific activity of 5 × 10 6 B-cell stimulatory factor 2 U/mg of protein, was produced in the Escherichia coli expression system and purified to homogeneity by gel filtration and ion exchange high-performance liquid chromatography (31) . Specific MAPK inhibitors, PD98059 and SB203590, were from Calbiochem (San Diego, CA). Agonistic (B-S12) and antagonistic (B-R3) monoclonal antibodies (mAbs) raised against the ectodomain of gp130 were from Diaclone Research (Besançon, France). electrophoresis and were double digested with EcoRI/KpnI. C/EBPα cDNA was released from pPC22-C/EBPP-α plasmid (a kind gift from Dr. J. P. Condreay) (32) by EcoRI/KpnI digestion. C/EBP inserts were ligated into the adenoviral pAC/CMVpLpA plasmid previously digested with EcoRI/KpnI. Sequence analysis of LAP and LIP revealed 100% identity with the previously published human C/EBPβ sequence (AC:P17676).
Murine STAT3 and STAT3-F cDNAs (a kind gift from Dr. T. Hirano) were released from the expression vector pCAGGS (33) with HgaI/BglII, and the restriction endonuclease termini were filled in by Klenow treatment. Inserts (2.4-2.5 kb) were subcloned by blunt-end ligation into pAC/CMVpLpA plasmid previously linearized, calf intestinal alkaline phosphatase dephosphorylated, and Klenow treated. The presence of inserts in the sense orientation was confirmed by restriction enzyme digestion and sequence analysis.
Generation of adenoviral expression vectors
The recombinant pAC/CMVpLpA plasmids (transfer vectors) were cotransfected with pJM17 into 293 cells (AdE1A-transformed human embryonic kidney cells) by coprecipitation of calcium phosphate and DNA (34) . The expression cassette of pAC/CMVpLpA is located between the sequences representing 0-1.3 map unit (mu) and 9.2-16 mu of adenovirus type 5, whereas pJM17 encodes a full-length adenovirus-5 genome (dl309) interrupted by the insertion of the bacterial plasmid pBRX at position 3.7 mu, thereby exceeding the packaging limit for adenovirus. Homologous recombination between adenovirus sequences in the transfer vector (recombinant pAC/CMVpLpA) and in the pJM17 plasmid results in the substitution of the pBRX sequences in pJM17 by the chimeric gene. This generates a genome of packageable size in which most of the adenovirus early region 1 is lacking, thus rendering the recombinant virus replication defective.
The resulting viruses (named Ad-LAP, Ad-LIP, Ad-C/EBPα, Ad-STAT3, and Ad-STAT3-F) were plaque purified, expanded into a high-concentration stock, and titrated by plaque assay as previously described (35) .
Cell culture and transduction with adenoviruses
The human hepatoma BC2 cells (36) were cultured in a mixture of 75% modified Eagle's medium and 25% medium 199 supplemented with 10% of FCS, 1 mg/ml bovine serum albumin, 7 × 10 −7 M insulin and hydrocortisone hemisuccinate. Cells were seeded in 3.5-cm plates and were cultured for 21 days until maximal differentiation. HepG2 cells were plated in Ham's F-12/Leibovitz L-15 (1:1, v/v) supplemented with 7% newborn calf serum and cultured to 70% confluence. Human hepatocytes were isolated from liver biopsy samples (1-3 g) from patients undergoing liver surgery after informed consent. None of the patients were habitual consumers of alcohol or other drugs. A total of four liver biopsy samples (1 male and 3 female subjects, ages ranging from 27 to 70 years) were used. Hepatocytes were isolated using a two-step perfusion technique (37) h, the culture medium was changed to serum-free medium containing 10 −8 M dexamethasone.
Cultures were routinely supplemented with 50 U/ml penicillin and 50 µg/ml streptomycin.
Hepatomas and primary hepatocytes were infected with recombinant adenoviruses for 120 min at a multiplicity of infection (MOI) ranging from 1 to 50 plaque-forming units/cell. Thereafter, cells were washed and fresh medium was added. Forty-eight hours after transfection, cells were analyzed or were harvested and frozen in liquid N 2 .
Quantification of mRNA levels
Total cellular RNA was extracted with the RNeasy Total RNA Kit (QIAGEN, Valencia, CA), and contaminating genomic DNA was removed by incubation with DNase I Amplification Grade (Invitrogen Life Technologies, Barcelona, Spain). RNA (1 µg) was reverse transcribed as previously described (38) . Diluted cDNA (3 µl) was amplified with a rapid thermal cycler and reverse (5'-GAG CAA GAG AAA TGA AGA AAA CAA A-3') primers amplified a predicted 643-bp DNA fragment. In parallel, we analyzed glucose-6-phosphate dehydrogenase (accession X03674) as an internal control for normalization. Its forward (5'-GCC CCT CGC TGC TGC TAC TA-3') and reverse (5'-CGC CCT CCT CCT TCC TTC TGT-3') primers produced a predicted 152-bp DNA fragment. PCR amplicons were confirmed to be specific by restriction and melting curve analysis. After denaturing occurred for 30 s at 95ºC, amplification was performed by 40 cycles of 1 s at 94ºC, 5 s at 58ºC, and 20 s at 72ºC. Real-time monitoring of the PCR reaction and precise quantification of the products in the exponential phase of the amplification were done by using the SYBR Green I format as recommended by the manufacturer.
Extraction of nuclear proteins and immunoblotting
Nuclear extracts from cultured hepatocytes were prepared as described earlier (39) and underwent electrophoresis in a sodium dodecyl sulfate-polyacrylamide gel (20 µg protein/lane).
Proteins were transferred to Immobilon membranes (Millipore, Bedford, MA), and sheets were incubated with two different rabbit polyclonal antibodies, one raised against a peptide of rat C/EBPα and one raised against the carboxyl terminus of C/EBPβ, or with goat polyclonal antibody raised against the carboxyl terminus of human HNF4α (Santa Cruz Biotechnology, Santa Cruz, CA 
RESULTS
IL-6 down-regulated CYP3A4 and induced APPs in human BC2 cells
The human-derived hepatocarcinoma BC2 cell line undergoes spontaneous differentiation in culture as it becomes confluent. We previously showed that 21-day confluent BC2 cells express drug biotransformation enzymes, notably CYPs, at levels that are much closer to those of human hepatocytes than any previously described human hepatoma cell line (36) . This property makes differentiated BC2 hepatoma cells a useful model to study CYP down-regulation by inflammatory cytokines.
Time course experiments with BC2 cells exposed to IL-6 at 100 U/ml showed that the downregulation of CYP3A4 mRNA began early (1.5 h) and reached the lowest value at about 6 h after treatment. Thereafter, a slow tendency to recover was observed (Fig. 1A) . Concomitantly, the mRNAs of two typical APPs (FIB and HAP) were induced by IL-6 with a similar profile (time course and fold increase) in human hepatocytes. There was a latency time of about 1.5 h followed by an increase in mRNA levels up to a maximum (three to four times the control value) at 6-9 h after IL-6 treatment began (Fig. 1B ).
The effect of IL-6 on CYP3A4 expression was dose dependent. Down-regulation was already noticeable at concentrations as low as 20 U/ml (about a 25% decrease); at higher IL-6 concentrations, CYP3A4 mRNA steadily decreased to 45-35% of control level at 120 U/ml IL-6 (data not shown).
IL-6 caused CYP3A4 down-regulation via interaction with the gp130 receptor
The transmembrane glycoprotein gp130 is a cytokine receptor subunit that is the common receptor component of the IL-6-type cytokines (i.e., IL-6, IL-11, oncostatin M [OSM], leukemia inhibitory factor [LIF], ciliary neurotrophic factor [CNTF], and cardiotrophin-1 [CT-1]). The binding of the cytokine to the receptor and the subsequent activation of gp130 initiate the cytoplasmic signal transduction cascades (17, 40) . To determine whether activation of gp130 by IL-6 is required for CYP3A4 down-regulation, we made use of several mAbs raised against the ectodomain of gp130 that have been characterized with respect to their agonistic or antagonistic properties (41) . The B-S12 antibody has been described as a potent agonist exerting IL-6-like responses on cells expressing gp130, whereas B-R3 is being recognized as antagonistic or inhibitory of gp130 activation by IL-6.
The results of our experiments clearly showed that incubation of BC2 cells with the agonistic antibody resulted in the simultaneous repression of CYP3A4 and induction of HAP, to an extent similar to that elicited by IL-6 ( Fig. 2) . In a parallel experiment, we found that the effects of IL-6 on the expression of both CYP3A4 and HAP could be significantly blocked with the antagonistic antibody ( Fig. 2) . Taken together, these experiments demonstrate that gp130 activation is absolutely required for CYP3A4 down-regulation by IL-6.
CYP3A4 down-regulation induced by IL-6 was independent of STAT3 activation
On the basis of previous experimental evidence, STAT3 has been recognized as the main STAT mediator of APP gene induction downstream of IL-6 and other gp130-related cytokines (42) (43) (44) . Consequently, we investigated whether STAT3 could also play a determinant role in the downregulation of CYP genes by IL-6. To investigate this possibility, we constructed recombinant adenoviral expression vectors encoding either the wild-type STAT3 (Ad-STAT3) or a dominantnegative variant of the STAT3 protein (Y705F), which is capable of competitively interfering with the activation of STAT3 by IL-6 (Ad-STAT3-F). The dominant-negative mutant Y705F cannot be phosphorylated in Tyr705, and thus it blocks recruitment of wild-type STAT3 to the receptor phosphopeptide docking sites and prevents its activation (45) .
When human hepatoma BC2 cells were transfected with increasing doses of STAT3 adenovirus (Ad-STAT3) and subsequently stimulated with IL-6, a dose-dependent increase in STAT3 protein and in its activated (Tyr705-phosphorylated) form was observed, as assessed by immunoblot analysis of nuclear extracts (Fig. 3) . However, overexpression of STAT3-F caused a dose-dependent decrease of the endogenous, IL-6-activated STAT3, revealing the dominantnegative nature of this mutant form (Figs. 3and 4A) .
In BC2 cells transfected with equimolar amounts of either Ad-STAT3 or Ad-STAT3-F, we found that FIB induction by IL-6 was completely inhibited in Ad-STAT3-F-transduced cells, whereas it was similar to controls in Ad-STAT3-transduced cells (Fig. 4C) . Similarly, HAP induction was inhibited from 3.47-fold over control in cells expressing Ad-STAT3 to 1.52-fold in cells expressing the dominant-negative STAT3-F variant (data not shown). Interestingly, under the same experimental conditions CYP3A4 down-regulation proceeded normally, independently of STAT3 activation (Fig. 4B ). This result clearly excluded the involvement of the JAK/STAT pathway in CYP down-regulation.
Specific MAPK inhibitors did not block CYP3A4 down-regulation
IL-6 can also act through the SHP-2/Ras/MAPK pathway. The MAPK family can be divided into two major categories, the extracellular-regulated kinases (ERKs) (46) and the stress-activated protein kinases (SAPKs/p38) (47) , which are modulated by multicomponent signal transduction cascades. Several reports have demonstrated activation of both types of MAPKs in response to IL-6 in hepatoma cells (18, 48) .
To evaluate the biological significance of MAPK pathways in the IL-6-induced down-regulation of CYP3A4, we used two specific inhibitors: PD98059, a selective and potent inhibitor of the ERK1/2 MAPKs, which binds to inactive MAPK/ERK kinase (MEK) and prevents phosphorylation and activation by Raf; and SB203590, which has been shown to specifically inhibit the p38 pathway.
BC2 cells were preincubated with increasing concentrations of MAPK inhibitors followed by 14 h of incubation with IL-6. The ERK1/2 inhibitor PD98059 did not abolish CYP3A4 downregulation, although it could inhibit FIB induction in a dose-dependent manner (Fig. 5) . Similarly, the p38 inhibitor SB203590 was not able to block CYP3A4 repression by IL-6, whereas it significantly inhibited FIB induction from a 2.45 ± 0.78-fold increase in controls (n = 4) to a 1.26 ± 0.09-fold increase in cells treated with 50 µM inhibitor (n = 3), P < 0.05.
IL-6 induced C/EBPβ-LIP (20-kDa) protein in human hepatoma BC2 cells
C/EBPβ is another transcription factor involved in IL-6 signal transduction, whose binding activity and transactivating capacity are induced in hepatoma cells by treatment with IL-6 (22, 24) . To explore the implication of C/EBPβ in the down-regulation of CYP3A4 by IL-6, we first stimulated human BC2 cells with IL-6 and analyzed C/EBPβ mRNA and protein levels at different time intervals. Subsequent to IL-6 stimulation, a fast but moderate increase in C/EBPβ mRNA up to two times the control value followed by a gradual decrease toward control levels was observed (Fig. 6A) . At the protein level, immunoblotting revealed a clear increase in C/EBPβ-LIP protein (20 kDa) concomitantly with mRNA induction (Fig. 6B) . In contrast, the amount of C/EBPβ-LAP (35 kDa), the major C/EBPβ form in nonstimulated cells, barely increased after IL-6 stimulation (Fig. 6B) .
Overexpression of LIP resulted in repression of CYP3A4 mRNA
To determine the relevance of LIP induction in the down-regulation of CYP3A4, we overexpressed LIP in hepatic cells by means of an adenoviral vector and measured the effect on CYP3A4 mRNA levels. As expected, transduction of BC2 cells with increasing doses of Ad-LIP resulted in a dose-dependent increase in LIP protein (Fig. 7A) .
Ad-LIP transfection had a clear negative effect on basal CYP3A4 mRNA levels, which was statistically significant at 20 and 50 MOI (about a 60% decrease from control transfection, P<0.05). This inhibitory effect must be attributed to LIP protein expression, as nonsignificant effects were observed in parallel transfection experiments with control (insert-less) adenovirus (Fig. 7B) . HAP is a recognized target for several C/EBP proteins, among them LIP (49) . Hence, endogenous HAP expression was also measured in the same RNA samples to demonstrate the correct function of the expressed LIP protein. Ad-LIP transfection in BC2 cells resulted, as expected, in a decrease in HAP mRNA levels, although somewhat less pronounced than that observed for CYP3A4 (Fig. 7C) .
LIP down-regulated CYP3A4 expression by antagonizing the activating effects of C/EBPα and C/EBPβ-LAP
Two constitutive C/EBP factors---C/EBPα and C/EBPβ-LAP---were investigated to assess their role as transactivators of the CYP3A4 gene. To this end, we developed recombinant adenoviruses encoding C/EBPα and C/EBPβ-LAP and transfected HepG2 cells. Basal levels of constitutive C/EBP proteins are lower in these human hepatoma cells, and they are therefore more suitable for assessment of the function of these factors in overexpression experiments. Increasing concentrations of Ad-C/EBPα caused a dose-dependent rise in C/EBPα protein and a concomitant induction of CYP3A4 and HAP mRNAs (Fig. 8A ). Differences from the control level were statistically significant at concentrations of adenovirus higher than 2.5 MOI (P<0.05), but the maximal increase in CYP3A4 mRNA levels (9.4 ± 2.9 fold, n = 4) was larger than that observed for HAP (5.9 ± 1.9 fold, n = 4). Transfection of cells with Ad-C/EBPβ-LAP at 20 MOI resulted in a significant threefold increase in CYP3A4 mRNA (P<0.05), which was a less pronounced up-regulation than that observed with C/EBPα. HAP mRNA, a positive control for C/EBPβ activity (49), was induced to a similar degree (Fig. 8B) .
The mechanism by which LIP down-regulates CYP3A4 could be explained in terms of competition between the truncated C/EBP isoform and the full-length heterodimerization partners (e.g., C/EBPβ-LAP and C/EBPα) for the same binding site(s). Factors of the C/EBP family can form homodimers and heterodimers with other members of the family, but, as LIP is devoid of the N-terminal activation domain, formation of heterodimers with full-length C/EBPs may result in the abolishment of their activating effects on transcription (29) . To explore the feasibility of this hypothesis, we carried out cotransfection experiments with both the activating C/EBP forms (C/EBPα and C/EBPβ-LAP) and the LIP factor.
Transduction of HepG2 cells with selected doses of either Ad-C/EBPα or Ad-C/EBPβ-LAP resulted, as expected, in activation of CYP3A4 expression. Coinfection with Ad-LIP resulted in a significantly lower CYP3A4 expression (Fig. 9A ), whereas coinfection with an equivalent dose of a control adenovirus (Ad-pACC) had no effect (data not shown). The most remarkable inhibition of LIP was observed with the C/EBPα-mediated induction of CYP3A4 (a 45% decrease in the presence of 40 MOI of Ad-LIP). A similar repressive effect was observed in experiments in which LIP was cotransfected with C/EBPβ-LAP (35-40% lower CYP3A4 expression).
Appropriate control assays by Western immunoblotting demonstrated that infection of hepatoma cells with the two different recombinant adenoviruses did not affect the expression of the respective coding transgenes. Figure 9B shows how expression of C/EBPα did not change when increasing doses of LIP were coexpressed (lanes 3-5). Similarly, the level of LIP transfected was not affected by the expression of C/EBPα (Fig. 9B, lanes 2 and 5) . Furthermore, the endogenous expression of HNF4α, which is also an important hepatic activator of CYP3A4, was not altered, despite the increased number of adenoviral particles per cell (MOI) in coinfection experiments (Fig. 9B) .
LIP effectively repressed CYP3A4 expression in human hepatocytes
To assess the relevance of our results in a model closer to human liver, we examined the effect of LIP on the expression of CYP3A4 in a primary culture of human hepatocytes. Human hepatocytes in culture, although resistant to transfection by classic methods, tolerated transfection with adenoviral vectors very well; almost 100% of the hepatocytes effectively expressed the transgene, as evidenced by the fluorescence microscopic image taken after transduction with Ad-green fluorescent protein (Ad-GFP) (Fig. 10A) .
Transfection of human hepatocytes with Ad-LIP caused an increase in LIP protein and, simultaneously, a clear repression of CYP3A4 mRNA levels, whereas transfection with empty vector (Ad-pAC) did not significantly change control levels (data not shown). The repressive effect of LIP was consistently reproduced in hepatocytes from four liver donors. Dose-response experiments (3-30 MOI of Ad-LIP) indicated that CYP3A4 down-regulation reached a plateau (40-50% inhibition), which was already attained at a low concentration of the exogenously expressed factor (Fig. 10B ). This percentage of down-regulation is close to that found after treatment of human hepatocytes with IL-6 (100 U/ml, 48 h), 56 ± 9% inhibition (n = 3).
DISCUSSION
In the present study, we examined in detail the mechanisms by which IL-6, a major signal during inflammation in humans, down-regulates the expression of CYP3A4 in hepatocytes at the same time that it triggers the synthesis of APPs (Fig. 1 ).
IL-6 shares with other proinflammatory cytokines (IL-11, LIF, OSM, CNTF, and CT-1) the common receptor subunit gp130, which is a key element in the signal transduction cascades leading to the up-regulation of APPs. IL-6 and other cytokines of this group (50) are also able to down-regulate CYP expression in hepatocytes. Both actions are likely to be associated with the binding of the cytokine to gp130, thus pointing to this receptor constituent as the common transducing step for both biological events. This assertion is sustained by the experimental results depicted in Fig. 2 showing that activation of the gp130 receptor by an IL-6-independent mechanism (agonistic mAb) also leads to CYP down-regulation, whereas blocking the receptor binding site with an antagonistic mAb prevents IL-6-mediated CYP repression. These observations support the notion that activation of gp130 is also at the root of CYP3A4 downregulation by IL-6-type cytokines.
The gp130 receptor subunit can activate two major signal transduction pathways (the JAK/STAT and the SHP-2/Ras/MAPK pathways), as well as other poorly characterized transduction routes (51) . As far as induction of APPs is concerned, STAT3 is recognized as the most important activated transcription factor downstream of gp130 (42, 43) . Recent studies with conditional mutant mice have shown that STAT3 is indeed essential for the up-regulation of all IL-6-inducible APPs genes such as SAP, FIB, HAP, and AGP (44) . Consequently, we investigated whether STAT3 would also be an essential player in the down-regulation of CYP3A4. To unequivocally answer this question, we made use of a dominant-negative STAT3 adenoviral expression vector and elegantly demonstrated how it is possible to block FIB and HAP induction by IL-6 but leave unaffected the down-regulation of CYP3A4 in human hepatic cells (Fig. 4) . Thus, the possibility that the down-regulation of CYP3A4 by IL-6-type cytokines proceeds through the JAK/STAT pathway has been excluded.
The second best characterized IL-6 transduction pathway downstream of gp130 involves activation of SHP-2, Ras, and MAPKs. Several targets for MAPKs are known, namely, ERK1, ERK2, p38, and SAPKs. Upon activation by MAPKs, ERKs phosphorylate and regulate the activities of several transcription factors, among them Jun, Fos, Elk-1, cyclic AMP-responsive element binding protein (CREB), and serum response factor (52) . Similarly, p38 and SAPKs, once activated, regulate transcription factors such as ATF2, Elk-1, and Jun (53) (54) (55) . After IL-6 stimulation, activation of both ERKs and p38 has been reported in human hepatoma cells (18, 48) .
To assess the relevance of this pathway in the down-regulation of CYP3A4, we made use of two kinase inhibitors: PD98059, which is recognized as a selective inhibitor for MEK1 phosphorylation and ERK1/2 activation (56), although some studies suggest other MEK-like kinases might also be sensitive to this inhibitor (57) , and SB20358, which is a specific inhibitor of p38 and is capable of abolishing HAP induction by IL-6 in HepG2 cells (48) . Our experiments with BC2 cells incubated with these inhibitors showed a significant attenuation of FIB induction by IL-6 but an unaltered down-regulation of CYP3A4 (Fig. 5) . Taken together, these data do not support a relevant role of ERK1/2 and p38, acting through the SHP-2/Ras/MAPK pathway, in the IL-6-mediated down-regulation of CYP3A4.
C/EBPβ is another transcription factor involved in IL-6 signal transduction (22, 24) . In noninduced conditions, the C/EBP binding sites of AP promoters contain C/EBPα homodimers and C/EBPα/C/EBPβ heterodimers (21) . However, in the course of AP induction, the amount of complexes containing C/EBPα is dramatically reduced and replaced by C/EBPβ and C/EBPδ (19) . There are several mechanisms to explain this phenomenon. Cytokines, such as IL-6, upregulate transcription of C/EBPβ and C/EBPδ and increase their respective expression levels (22, 23) . IL-6 also triggers the activation of preexisting nuclear C/EBPβ by a post-translational mechanism, which does not require de novo protein synthesis (24) (25) (26) (27) . In this regard, Rasdependent Thr phosphorylation of C/EBPβ appears to be of relevance (58) . Finally, inflammatory stimuli and cytokines can also modify the relative abundance of the major C/EBPβ protein isoforms, which can be translated from the same C/EBPβ mRNA (LAP, 32-35 kDa, and LIP, 20 kDa). Increased expression of LIP has been reported during the APR (30) and after stimulation with proinflammatory cytokines such as IL-6, IL-1, and TNF-α (23, 59, 60).
When we investigated the effect of IL-6 on C/EBPβ expression in differentiated human hepatoma cells, we found a moderate up-regulation of mRNA but a dramatic increase in the low molecular weight isoform LIP, which was barely detectable by immunoblotting in nuclear extracts from nonstimulated cells (Fig. 6) . It is worth emphasizing that the 20-kDa protein LIP is proposed to function as a dominant-negative regulator of full-length C/EBP proteins, as it lacks most of the transactivation domain but contains the DNA binding and dimerization domains. Thus, LIP is involved in the down-regulation of the alpha1(I) collagen gene by TNF-α (60, 61) , and in the down-regulation of the closely related C/EBPα gene during the APR (62) . Our experiments with an adenoviral vector for LIP agree with this view. By overexpressing LIP in hepatoma cells, it was possible to demonstrate a clear inhibitory effect on CYP3A4 expression without influencing the LAP content of cells (Fig. 7) . LIP also had a moderately inhibitory effect on basal HAP levels, as previously noted by Natsuka et al. (49) . Thus, the effect of LIP is less determinative for IL-6-induced APPs, which, in turn, are strongly up-regulated via STAT3.
On the basis of these results, our next aim was to decipher the mechanism by which LIP inhibits CYP3A4 expression during inflammation. Previous experimental data supported the operation of a competition model among LIP and other C/EBP forms, such as C/EBPα and C/EBPβ-LAP. Indeed, LIP, in sub-stoichiometric concentration, forms heterodimers with LAP, reducing its transcription potential and showing higher DNA binding activity (29) . Moreover, LIP can also form heterodimers very efficiently with C/EBPα (24) , but the relevance of this to CYP3A4 down-regulation must be demonstrated.
Competition by LIP would be effective only if both C/EBPα and C/EBPβ-LAP would act as constitutive transcriptional activators of CYP3A4. The feasibility of this competition mechanism was examined with the aid of adenoviral vectors encoding the two most abundant C/EBP proteins in the liver: C/EBPα and C/EBPβ-LAP. Overexpression of any of these factors in human hepatoma cells caused up-regulation of CYP3A4 and HAP, a well-characterized target for C/EBPs (Fig. 8 ). This experiment confirmed the positive role exerted by C/EBPα and C/EBPβ-LAP in the regulation of endogenous human CYP3A4, in its native chromatin context. Previous reports by Ourlin et al. (63) , showing transactivation of CYP3A4 promoter constructs by C/EBPα, would be in agreement with our findings. A positive role of C/EBPβ-LAP on CYP3A4 has not been previously reported.
The proof of the proposed mechanism was investigated by cotransfecting cells with the corresponding adenoviral constructs. The adenoviral transfection allowed not only the fine tuning of transgene expression and the coexpression of the two transgenes with high efficiency (nearly 100%) but also the evaluation of effects of the trans-acting factors on the endogenous CYP3A4 gene in its native chromatin structure. The experiments summarized in Fig. 9 clearly demonstrated that an increase in LIP expression can significantly reduce the activating effect of C/EBPα and C/EBPβ-LAP on the CYP3A4 gene to 55%. Notably, this value is similar to that observed after IL-6 treatment of cells. A similar mechanism (i.e., displacement of C/EBPα from the D site in the albumin promoter and transactivation interference) has also been proposed for albumin down-regulation during liver regeneration (64) .
To assess the relevance of our observations to human liver, we examined whether LIP could effectively impair CYP3A4 expression in cultured human hepatocytes, which is recognized as being the closest model to human liver. Indeed, human hepatocytes maintain in culture a much higher level of hepatic-specific functions and liver-enriched transcription factors than do hepatomas (37, (65) (66) (67) . In cultured hepatocytes, a moderate increase in LIP expression downregulated CYP3A4 mRNA (Fig. 10) , thus demonstrating that the repressive mechanism of LIP on CYP3A4 operates in a human-relevant model.
Several mechanisms have been proposed to explain the down-regulation of CYP genes by inflammatory responses. Thus, TNF-α is believed to represses CYP1A1 via redox regulation of nuclear factor-1 (68), whereas IL-2 down-regulates rat CYP2C11 and CYP3A2 expression probably via induction of the proto-oncogene c-myc (69) , and IL-1 inhibits CYP2C11 transcription via binding of NF-κB to a low-affinity binding site in its promoter (70) . Nuclear receptors have also been claimed to be relevant factors in the mechanism of CYP repression, as a decreased expression of PXR and CAR was observed after IL-6 incubation (71), and downregulation of several CYPs was blocked in PPARα −/− mice after treatment with LPS (72).
In the case of IL-6, the results of our research point to an increased expression in C/EBPβ-LIP as the determining event. This truncated C/EBPβ protein, by competing with other constitutive C/EBP-activating factors, particularly C/EBPα, down-regulates the expression of human CYP3A4.
Inflammation is a common damage-associated response in the population, but as far as CYP down-regulation is concerned, the increasing number of therapeutic cytokines (e.g., interferons, IL-2, IL-11, erythropoietin, or granulocyte-colony stimulating factor) can also play an important role. Their repressive potential on drug-metabolism should be considered and, in this regard, our findings could be relevant for the development of therapeutic cytokines with no negative effect on hepatic drug-metabolizing enzymes. increasing amounts (µl/ml) of a gp130 agonistic mAb (B-S12) or an antagonistic mAb (B-R3), and 5 min later IL-6 (120 U/ml) was added as indicated. After 9 h of incubation, the mRNA levels of CYP3A4 (A) and HAP (B) were measured by quantitative RT-PCR analysis. Data represent means ± SD from three independent cultures. ***P < 0.005; **P < 0.01; *P < 0.05. The blocking of STAT3 activation abolished FIB induction by IL-6 (C) but had no effect on CYP3A4 down-regulation (B). Black bars, IL-6-treated cells; white bars, controls. Data represent means ± SD from three or four independent cultures. ***P < 0.005; **P < 0.01. . BC2 cells were exposed to IL-6 (100 U/ml), and at different time points after treatment we analyzed C/EBPβ mRNA by quantitative RT-PCR (n = 2) (A). We also analyzed the level of the two translation products (LAP, 35 kDa; and LIP, 20 kDa) by immunoblotting with an anti-C-terminal-C/EBPβ antibody, which recognizes both products (B). 
